Biotech Startups
9,603 companies tagged Biotech, with their investors and founders.
CuraSen Therapeutics is a privately funded biopharmaceutical company developing treatments that selectively activate adrenergic receptors in the brain to restore noradrenergic signaling. It targets psychiatric and neurodegenerative conditions including Parkinson's disease, Alzheimer's disease, neurogenic orthostatic hypotension, PSP, and ALS.
4 investors
Curevo Vaccine is a clinical-stage biotech company developing non-mRNA vaccines, with a lead adjuvanted subunit vaccine candidate (amezosvatein/CRV-101) for shingles and chickenpox. The company is running a Phase 2 program comparing amezosvatein head-to-head against Shingrix and plans a Phase 1 trial in immunocompromised children.
4 investors
Curocell is a Korean biotech company developing CAR-T cell therapies for cancers such as lymphoma and leukemia, as well as autoimmune conditions like lupus. Its lead therapy anbalcel (marketed as Limkato) received manufacturing/marketing approval, making it one of Korea's most advanced CAR-T-focused companies.
4 investors
CVRx develops Barostim, an implantable medical device that uses baroreceptor activation to treat heart failure patients and improve their functional capacity and quality of life.
4 investors
Gilead Sciences is a biopharmaceutical company that develops medicines across virology, oncology, and inflammation, with more than 25 medicines offered globally and a clinical pipeline spanning these three therapeutic areas. The content served corresponds to Gilead rather than CymaBay.
4 investors
Damona develops precision neuromedicines aimed at treating cognitive deficits associated with neurodegenerative and psychiatric disorders such as Alzheimer's disease, depression, and schizophrenia. Its lead drug targets a specific subunit of the GABA-A receptor to improve neuronal function and reverse cognitive impairment.
4 investors
Dash Bio is a contract research organization (CRO) offering bioanalysis services with a technology-based, automated approach, delivering sample analysis results in days. It provides method development and validation, ELISA/MSD, LC-MS, and qPCR assays across preclinical to late-stage clinical studies for pharmaceutical and biotech companies.
4 investors
De Novo Food Labs produces nature-identical bovine lactoferrin (branded NanoFerrin) using precision fermentation instead of dairy extraction, offering customizable iron saturation, purity, and sequence identity per batch. It supplies formulators of products such as infant formula, gut-health blends, and iron supplements with lactoferrin at lower cost and higher, more consistent volumes than traditional dairy sourcing.
4 investors
DeepLife is an AI techbio company that develops digital twin technology to simulate cellular behavior and disease mechanisms at the single-cell level. The platform integrates multi-omics data and causal AI to accelerate drug discovery and development for diseases with significant unmet medical needs.
4 investors
Denali Therapeutics develops therapeutics for neurodegenerative diseases. The company focuses on discovering and developing novel drug candidates targeting specific neurological conditions.
4 investors
Diagonal Therapeutics develops multi-specific clustering antibody therapeutics that bind multiple cell-surface receptors to activate or inhibit dysregulated signaling pathways underlying chronic diseases. Its DIAGONAL Product Engine uses computational and experimental methods to identify clustering antibodies across receptor classes, with a lead candidate (DIAG723) in a Phase 1/2 trial for Hereditary Hemorrhagic Telangiectasia.
4 investors
DiscureMD is developing a treatment focused on disc degeneration, a leading cause of back pain that affects most adults during their lifetime.
4 investors
Earli develops a biotechnology platform that uses genetic constructs to detect cancer and produce therapeutic proteins by reprogramming cancer cells. The company focuses on oncology diagnostics and therapeutics for cancer patients.
4 investors
Eclipsebio provides RNA biology analytical services and sequencing-based assays that help drug developers and researchers characterize RNA at nucleotide-level resolution and generate datasets for AI-driven drug discovery. It serves pharma, biotech, and academic partners working on oligonucleotides, RNA-targeting small molecules, and fundamental RNA research.
4 investors
Edifice Health offers the Inflammatory Age test, a biomarker composite scoring system that measures and monitors a person's inflammatory and immune health for early detection and prevention of chronic disease. The test, derived from Stanford University research using omics platforms and AI, is provided to clinics, physicians, and healthcare providers to help manage patients' chronic inflammation and longevity.
4 investors
Elegant Bio develops DNA synthesis technology and services, offering ENFINIA™ DNA synthesis at scale for biotech and research applications.
4 investors
ElevateBio is a contract development and manufacturing organization (CDMO) for advanced therapies, offering discovery, process development, analytics, manufacturing, and regulatory support for cell therapies, viral vectors, mRNA therapeutics, and gene editing. It partners with drug developers to bring cell and gene therapies from early discovery through commercial-scale cGMP manufacturing.
4 investors
Emerald Cloud Lab (ECL) provides remote, cloud-based access to a life science research laboratory, letting researchers run and automate experiments and workflows without a physical lab. It serves pharmaceutical, biotech, consumer products, academic, and contract research organizations across applications such as discovery, CMC, DMPK, and diagnostics.
4 investors
Emulate develops Organ-Chip technology, including 30+ organ models such as liver, brain, and other human tissue chips, used for human-based preclinical drug safety and toxicity testing. It serves pharmaceutical and biomedical researchers as a human-relevant alternative to animal testing, and works closely with the FDA including acceptance into the ISTAND pilot program.
4 investors
Enable Injections develops and manufactures enFuse, a wearable drug delivery device that delivers large volumes of pharmaceutical and biologic therapeutics subcutaneously for patients with chronic diseases. The company serves healthcare providers, payers, and patients by offering a mechanical hands-free alternative to intravenous treatment.
4 investors
Encellin develops next-generation therapies for patients with chronic unmet clinical needs, using technology originating from Dr. Tejal Desai's laboratory at UCSF that combines micro and nanotechnologies with novel drug delivery approaches. The company focuses on therapeutic delivery platforms and cell-based treatments, particularly for diseases including diabetes and autoimmune conditions.
4 investors
EnClear Therapies is a bio/med-tech company developing the EnTrega CSF platform, focused on cerebrospinal fluid-related therapies. It is built by a multidisciplinary team with experience in platform and commercial market development.
4 investors
EngageBio develops DNA-based medicines using proprietary non-viral delivery technology to achieve extended therapeutic expression from a single dose with low manufacturing complexity.
4 investors
Enliven Therapeutics is a biopharmaceutical company developing small molecule precision therapeutics, including ELVN-001, a selective active site inhibitor of BCR::ABL1 for patients with chronic myeloid leukemia (CML). It focuses on drug candidates with differentiated profiles across efficacy, tolerability, and dosing for clinical use.
4 investors